Lower sensitivity of nasal polyp fibroblasts to glucocorticoid anti-proliferative effects  by Pujols, Laura et al.
Respiratory Medicine (2011) 105, 218e225ava i lab le at www.sc iencedi rect .com
journal homepage : www.e lsev ie r . com/ loca te / rmedLower sensitivity of nasal polyp fibroblasts
to glucocorticoid anti-proliferative effectsLaura Pujols a,b,*, Mireya Fuentes-Prado a,b, Laura Ferna´ndez-Bertolı´n a,b,
Isam Alobid a,b,c, Jordi Roca-Ferrer a,b, Joaquim Mullol a,b,c,1,
Ce´sar Picado a,b,d,1aClinical and Experimental Respiratory Immunoallergy, Institut d’Investigacions Biome`diques August Pi i Sunyer (IDIBAPS),
Hospital Clı´nic, Villarroel 170, 08036 Barcelona, Catalonia, Spain
bCentro de Investigaciones Biome´dicas en Red de Enfermedades Respiratorias (CIBERes), Fundacio´n Caubet-Cimera,
Recinto Hospital Joan March, Carretera Soller Km 12, 07110 Bunyola, Mallorca, Illes Balears, Spain
cUnitat de Rinologia i Clı´nica de l’Olfacte, Servei d’Otorinolaringologia, Hospital Clı´nic, Villarroel 170, 08036 Barcelona,
Catalonia, Spain
d Servei de Pneumologia i Al,le`rgia Respirato`ria, Hospital Clı´nic, Universitat de Barcelona, Barcelona, Catalonia, Spain
Received 24 March 2010; accepted 3 August 2010
Available online 9 September 2010KEYWORDS
Asthma;
Fibroblasts;
Glucocorticoids;
Nasal mucosa;
Nasal polyps* Corresponding author. Institut d’In
Barcelona, Catalonia, Spain. Tel.: þ3
E-mail address: lpujols@clinic.ub.e
1 Both authors contributed equally t
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2010.08.001Summary
Background: Treatment with glucocorticoids (GCs) is the cornerstone of nasal polyp (NP)
therapy, but some patients respond poorly to them. Fibroblasts are involved in both inflamma-
tion and remodelling of NP. We aimed to evaluate whether NP fibroblasts are less sensitive to
GCs’ anti-proliferative and anti-inflammatory effects, compared to nasal mucosa (NM) fibro-
blasts.
Methods: Fibroblasts were obtained from NP (nZ 8) from asthmatic patients undergoing endo-
scopic surgery and NM (n Z 8) from patients undergoing nasal corrective surgery. Fibroblasts
were stimulated with DMEM at 0.5% or 5% FBS, or TGF-b (5 ng/ml), with or without dexameth-
asone (1011 to 105M) for different times. Cell proliferation, collagen mRNA expression and IL-
6 and IL-8 release were measured.
Results: After 3-days, dexamethasone dose-dependently inhibited proliferation of NM
(p < 0.001) but not that of NP fibroblasts. Dexamethasone (106M) reduced by 25% the prolif-
eration of NM fibroblasts. Dexamethasone also inhibited proliferation of NM (p < 0.01) but not
that of NP fibroblasts at 5-days. TGF-b induced collagen-1a1, -1a2, and -3a1 mRNA levels in
both NM and NP fibroblasts (p < 0.05), and dexamethasone did not alter TGF-b-induced
collagen mRNA levels in either fibroblast type at 24 h. Dexamethasone dose-dependentlyvestigacions Biome`diques August Pi i Sunyer (IDIBAPS), lab 402. Hospital Clı´nic, Villarroel 170, 08036
4 932275400x3282; fax: þ34 934515272.
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Glucocorticoid effect on nasal fibroblasts 219decreased (p < 0.05) FBS-induced IL-6 and IL-8 release in both NM and NP fibroblasts at 4 h,
although at 108M, dexamethasone inhibited cytokine production in NM (p < 0.05) but not
in NP fibroblasts.
Conclusions: This impaired sensitivity of nasal polyp fibroblasts to in vitro glucocorticoid
effects concurs in part with the poor clinical response that these nasal polyp patients show
to glucocorticoid treatment.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Inflammation and remodelling, i.e., a pathological wound
repair mechanism, are hallmarks of both asthma and
chronic rhinosinusitis, with or without nasal polyposis.1
Chronic rhinosinusitis with nasal polyps (NP) reveals
frequent epithelial damage, a thickened basement
membrane, oedema, fibrotic foci and a reduced number of
vessels and glands. Compared with control NM, the stroma
of NPs contains abundant infiltration of inflammatory cells,
predominantly activated eosinophils and increased fibro-
blast numbers.1e3 Fibroblasts are the major and nearly
exclusive producers of extra-cellular matrix (ECM) proteins
in airways, including collagens, fibronectin and proteogly-
cans. Increased collagen and fibronectin deposition has
been found in NPs compared to NM.3,4 Fibroblasts also
release enzymes and a variety of pro-inflammatory medi-
ators, including growth factors, cytokines, and chemokines,
such as IL-6 and IL-8, which contribute to the perpetuation
of inflammatory and fibrotic processes in the airways.1,5,6
Among NP patients, those with associated asthma, and
especially thosewithaspirin-intolerantasthma,have increased
fibroblast proliferation and ECM deposition, and increased
fibroblast differentiation into myofibroblasts.7,8 As part of the
various structural changes observed, fibrotic alterations have
a great impact on the long-term outcome of NPs.8
Anti-inflammatory treatment with intranasal glucocor-
ticoids (GC) has been the cornerstone of NPs therapy.9e11
The main target of GC action is the inhibition of inflam-
matory cell activation and survival, although structural
cells, including fibroblasts, are also targets of GC treat-
ment.1 Some patients, however, do not respond, or respond
poorly, to GC therapy, resulting in a need for repeated
surgery to remove NPs.10
GCs appear to be little effective in reducing the thick-
ened basement membrane and airway-wall fibrosis.12
Indeed, long-term treatment with high doses of potent
inhaled GCs is usually required in adults with mild asthma
to reverse some of the changes resulting from remodel-
ling.13,14 In vivo treatment of NPs with intranasal flutica-
sone propionate did not decrease collagen deposition.4
In addition, contrasting effects of GCs have been
reported on airway fibroblast proliferation, with some
studies showing increased proliferation by GCs in fibroblasts
from asthmatic patients,15,16 and others reporting
decreased proliferation by GCs in NP fibroblasts.17,18 No
comparative studies of the anti-proliferative potency of
GCs in NM and NP fibroblasts have been reported to date.
The objective of the present study was to determine
whether fibroblasts from inflamednasal tissue, i.e. fibroblasts
from patients with NPs and asthma who have a poor clinicalresponse to GC therapy, are less sensitive to the inhibitory
effects of in vitro GCs, compared to NM fibroblasts.
Methods
Reagents
Dulbecco’s modified Eagle’s medium (DMEM) was obtained
from Lonza and foetal bovine serum (FBS) from Biological
Industries. Trypsin-EDTA, penicillin, streptomycin and
HEPES were purchased from Invitrogen, and amphotericin B
from Squibb. Dexamethasone (Fortecortin) was obtained
from MSD, and transforming growth factor (TGF)-b and
DuoSet ELISAs from R&D. The cell proliferation kit II (XTT)
was purchased from Roche Diagnostics, and the RNeasy Mini
kit and RT-PCR reagents from Qiagen and Applied Bio-
systems, respectively.
Subjects
NPs tissues were obtained from 8 patients with nasal pol-
yposis and asthma undergoing functional endoscopic sinus
surgery (FESS)(Table 1). NM was obtained from the inferior
turbinate of 8 subjects undergoing turbinectomy for turbi-
nate hypertrophy with or without septoplasty for nasal
septum deviation. All NP patients included herein had been
followed up in the Rhinology Unit & Smell Clinic, ENT
Department of our Hospital for at least one year prior to
surgery, and were assigned for surgery because they had
not shown an improvement by GC treatment in nasal
obstruction, rhinorrhea, and/or quality of life, as described
elsewhere.10,19 The diagnosis of severe nasal polyposis was
based on criteria described in the EP3OS document,10 i.e.,
nasal symptoms, nasal endoscopic examination, and CT
scan of paranasal sinus, as reported elsewhere.9 The diag-
nosis of asthma was established on the basis of the clinical
history and the demonstration of a reversible bronchial
obstruction. Diagnosis of aspirin intolerance was made on
the basis of a clear-cut history of asthma attacks precipi-
tated by non-steroidal anti-inflammatory drugs (NSAIDs),
and confirmed by aspirin nasal challenge in patients with an
isolated episode of NSAID-induced asthma exacerbation. No
subject from the NM group had a history of nasal or sinus
disease (chronic rhinitis/rhinosinusitis). One of the NM
subjects had been treated with intranasal GCs more than
one month prior to surgery (Table 1). None of the patients
had suffered from upper respiratory infection during at
least the 2 weeks prior to surgery. All subjects agreed to
participate in the study, which was approved by the Ethics
Committee of our Institution.
Table 1 Demographic data and clinical characteristics of
the study population.
Nasal
mucosa
Nasal
polyps
Patients (n) 8 8
Female, n (%) 3 (37.5) 4 (50)
Age, years (mean  SEM) 39.4  3.9 41.0  4.0
Asthma, n (%) 0 (0) 8 (100)
Aspirin intolerance, n (%) 0 (0) 4 (50)
Intranasal glucocorticoids, n (%) 1 (12.5) 7 (87.5)
Skin prick test positivity, n (%) 1 (12.5) 3 (37.5)
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Fragments (approximately 3  3 mm) of the nasal tissues
were placed in 6-well culture dishes in DMEM supplemented
with 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin,
and 2 mg/ml amphotericin B, in a humidified atmosphere at
37 C and 5% CO2. Fibroblasts were isolated from the tissue
fragments through adhesion and migration on the plastic
surface. Once fibroblast cultures had reached 80% conflu-
ence, i.e. after a minimum of 3 weeks, the tissue fragments
were removed and adhered cells were trypsinised (0.05%
trypsin-0.02% EDTA) and sub-cultured in 150 cm2 flasks. The
purity of fibroblasts cultures was determined by immunocyto
chemistry of cytokeratin and vimentin. Briefly, fibroblasts
cultured in 4-well culture slides were washed with PBS, fixed
with 4% paraformaldehyde (15 min), permeabilised with
0.2% Triton X-100 (10 min), blocked with 1% bovine serum
albumin-PBS (1 h), incubated first with primary antibodies
(1 h, 37 C) against vimentin (V5255, Sigma) or pan-cyto-
keratin (C2562, Sigma) and then with fluorescent secondary
antibody (1 h), and stained (nuclei) with DAPI (1/10,000
dilution). Finally, slides were mounted using Prolong Gold
antifade reagent (Invitrogen). The percentage of positive
cells was quantified using fluorescence microscopy. After
the second passage, 100% of both NM and NP cell cultures
were cytokeratin-negative and vimentin-positive (Fig. 1).
Fibroblast cultures were also tested for mycoplasmaFigure 1 Representative immunofluorescent staining image of c
(green fluorescence) in the cytoplasm of cultured cells, and (B)
confirming the absence of epithelial cells in the cultures. Origina
colour in this figure legend, the reader is referred to the web verscontamination using a PCR-based mycoplasma detection kit
(VenorGeM, Minerva Biolabs). In all experiments, prior to
drug incubation, cells were growth-arrested by incubation
with serum-free medium for 18e24 h. Experiments were
carried out between passages 4 and 8.
Cell proliferation
Fibroblasts were plated in 96-well culture plates
(1  103 cells/well). The following day, cells were growth-
arrested as indicated above and incubated with cell medium
supplemented with 0.5% FBS, in the absence or presence of
dexamethasone at 1011 to 105M, for 3 and 5-days. The cell
medium, with or without dexamethasone, was changed at
day 3 in cells incubated with dexamethasone for 5-days.
After treatment, cell proliferation was determined using the
colorimetric Cell Proliferation Kit II (XTT). Absorbance was
measured on a microplate spectrophotometer at 490 nm.
Collagen mRNA expression
Fibroblasts were plated in 6-well culture plates (105 cells/
well). Sub-confluent cell cultures were growth-arrested as
indicated above, pre-incubated with dexamethasone
(1010M, 108M, and 106M) for 1 h, and then incubated
with transforming growth factor (TGF)-b (5 ng/ml) for 24 h.
Total RNA from cell cultures was extracted using the
RNeasy Mini kit. One microgram of total RNA was converted
to cDNA using the High-Capacity cDNA Reverse Transcrip-
tion Kit. The mRNA expression of collagens 1a1, 1a2, and
3a1 was analyzed by real-time PCR (7900HT Fast Real-Time
PCR System, Applied Biosystems) using TaqMan Fast
Universal PCR Master Mix and TaqMan Gene Expression
Assays (Assay ID’s: Hs00164004_m1, Hs00164099_m1,
Hs00164103_m1, Applied Biosystems).
IL-6 and IL-8 production
Fibroblastswereplated in24-well cultureplates (3104cells/
well). Sub-confluent cell cultures were growth-arrested as
indicatedabove,pre-incubatedwithdexamethasone(1010M,ontrol NM fibroblasts showing (A) presence of vimentin fibers
total absence of immunofluorescent staining for cytokeratins,
l magnification 200. (For interpretation of the references to
ion of this article).
Glucocorticoid effect on nasal fibroblasts 221108M, and 106M) for 1 h, and then stimulated with cell
medium supplementedwith 5% FBS. Cell culture supernatants
were collected at 4 h post-stimulus. IL-6 and IL-8 production in
supernatants were measured by ELISA. Cytokine production
(pg/ml) was corrected by cell number using the XTT assay.
Statistical analysis
Data are expressed as median and 25th to 75th percentile. A
non-parametric statistical analysis was performed using the
Friedman test and Wilcoxon rank test for with in-group
comparisons, and the KruskaleWallis test andManneWhitney
U test for between-group comparisons. Statistical signifi-
cance was set at p < 0.05.
Results
Effect of dexamethasone on fibroblast proliferation
Dexamethasone treatment for 3-days provoked a dose-
dependent inhibition of cell proliferation in fibroblasts from
NM (p < 0.001) but not in fibroblasts from patients with NPs
(Fig. 2A). The inhibitory effect of dexamethasone on the
proliferation of NM fibroblasts was modest, thus causing
a 25% inhibition of cell proliferation at the highest dexa-
methasone concentrations compared to control cells
(Fig. 2A). As shown in Table 2, fibroblasts from NPs, and
particularly those from aspirin-intolerant asthmatics (AIA),
were more resistant to the anti-proliferative effect of
dexamethasone. In common with the 3-day treatment,A Nasal mucosa
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Figure 2 Effect of dexamethasone on fibroblast proliferation. Eff
on the proliferation of NM (left graphs) and NP fibroblasts (right g
intolerant (solid triangles) asthmatic patients. The median value i
with DMEM 0.5% FBS) by Wilcoxon test.incubation of cells with dexamethasone for 2 additional
days dose-dependently inhibited cell proliferation in fibro-
blasts from NM (p < 0.01) but not in NP fibroblasts (Fig. 2B).
The inhibitory effect of dexamethasone on cell prolifera-
tion was not due to induction of cytotoxicity, as demon-
strated by determining lactate dehydrogenase (LDH)
activity in cell culture supernatants (data not shown).Effect of dexamethasone on collagen mRNA
expression
We then investigated the capacity of dexamethasone to
reduce the fibrogenic function of nasal fibroblasts by
measuring the effect of dexamethasone on the mRNA
expression of collagen types 1a1, 1a2 and 3a1. To stimu-
late the mRNA expression of collagens, nasal fibroblasts
were incubated with TGF-b. As shown in Fig. 3, TGF-
b induced the mRNA expression of collagens 1a1 (Fig. 3A),
1a2 (Fig. 3B) and 3a1 (Fig. 3C) in fibroblasts from both NM
and NPs. No significant differences in the extent of mRNA
induction of the three collagen types by TGF-b were found
between NM and NP fibroblasts, or between ATA and AIA NP
fibroblasts (data not shown). Dexamethasone did not have
any significant effect on the TGF-b-induced collagen mRNA
expression either in NM or in NP fibroblasts (Fig. 3).
Incubation of nasal fibroblasts with a much less potent
fibrogenic stimulus, i.e. 5% FBS, did not significantly up-
regulate the mRNA expression of any collagen type, and
nor did dexamethasone decrease collagen mRNA expres-
sion of 5% FBS-treated fibroblasts (data not shown).125
150
175
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ect of (A) a 3-day and (B) a 5-day exposure with dexamethasone
raphs) from either aspirin-tolerant (open triangles) or aspirin-
s represented. *p < 0.05 compared to control (cells incubated
Table 2 Comparison of dexamethasone inhibition of cell proliferation in the different fibroblast subtypes.
Dexamethasone concentration (log M)
8 7 6
Nasal mucosa (NM) 81 (76e93) 76 (60e83) 73 (71e84)
Nasal polyps (NP) 102 (88e114)* 98 (93e118)* 103 (77e115)*
Aspirin-tolerant NP 90 (82e115) 95 (83e138)* 78 (69e105)
Aspirin-intolerant NP 103 (102e114)*,NS 109 (95e118)*,NS 113 (100e148)*,NS
Results expressed as median and 25ne75th percentile of the percentage of proliferation compared to untreated cells (100%). * p< 0.05
compared to nasal mucosa and NS Z not significant compared to aspirin-tolerant nasal polyps, at the corresponding dexamethasone
concentration (ManneWhitney U test).
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production
Because fibroblasts also locally release cytokines and che-
mokines such as IL-6 and IL-8 that contribute to the main-
tenance of inflammation and remodelling of the airways,
we aimed to investigate the inhibitory effects of dexa-
methasone on IL-6 and IL-8 production in our nasal fibro-
blasts. As shown in Fig. 4, FBS treatment increased IL-6Figure 3 Effect of dexamethasone on TGF-b-induced collagen
dexamethasone (DEX) for 24 h (see Methods) and the mRNA express
and NP fibroblasts (right graphs) from either aspirin-tolerant (op
patients was analyzed by real-time PCR. The median value is repres
Wilcoxon test.(Fig. 4A) and IL-8 production (Fig. 4B) in fibroblasts from
both NM and NPs compared to FBS-deprived cells. Dexa-
methasone dose-dependently decreased FBS-induced IL-6
and IL-8 production in fibroblasts from both NM and NPs. For
both IL-6 and IL-8, NM fibroblasts appeared to be more
sensitive to the inhibitory effect of dexamethasone than NP
fibroblasts. Thus, a sub-maximal concentration of dexa-
methasone, i.e. 108M, inhibited IL-6 and IL-8 production in
NM fibroblasts but not in NP fibroblasts (Fig. 4). A similarmRNA expression. Fibroblasts were incubated with TGF-b and
ion of collagens (A) 1a1, (B) 1a2, and (C) 3a1 in NM (left graphs)
en triangles) or aspirin-intolerant (solid triangles) asthmatic
ented. )p <0.05 and #pZ 0.058 compared to untreated cells by
Figure 4 Effect of dexamethasone on IL-6 and IL-8 production. Fibroblasts were incubated with DMEM 5% FBS and dexameth-
asone (DEX) for 4 h (see Methods) and (A) IL-6 and (B) IL-8 release in cell culture supernatants from NM (left graphs) and NP
fibroblasts (right graphs) from either aspirin-tolerant (open triangles) or aspirin-intolerant (solid triangles) asthmatic patients were
measured by ELISA. The median value is represented. )p < 0.05 compared to untreated cells and yp < 0.05 compared to FBS-
treated cells by Wilcoxon test.
Glucocorticoid effect on nasal fibroblasts 223sensitivity to dexamethasone-mediated inhibition of IL-6
and IL-8 was found between ATA and AIA NP fibroblasts
(data not shown).Discussion
Our study shows that dexamethasone exerts regulatory
effects on fibroblast proliferation and the release of the
pro-inflammatory cytokines IL-6 and IL-8. We also report
that fibroblasts obtained from an inflamed and remodelled
tissue (nasal polyp) are relatively insensitive to the inhibi-
tory effects of dexamethasone, compared with those
obtained from non-inflamed NM. To our knowledge this is
the first study to compare the in vitro response of human
NM and NP fibroblasts to GCs.
The anti-inflammatory and immuno-suppressive effects
of GCs are partly mediated through the modulation of cell
proliferation. We found that dexamethasone provoked
a mild inhibition of cell proliferation in NM fibroblasts but
did not significantly inhibit proliferation of fibroblasts
derived from patients with NPs and asthma who had
undergone surgery due to their poor response to GC
therapy. This finding suggests that the presence of inflam-
mation and remodelling with in the NP of these patients
enhances resistance of nasal fibroblasts to GCs. Our findings
concur with clinical observations of GCs having almost no
effect on the treatment of diseases characterized by
a predominant fibrogenic component, such as interstitial
lung fibrosis.20 They also concur with findings on asthma,
where GCs have a limited capacity to reduce the remod-
elling process associated with the underlying inflamma-
tion.13,14 The lower effect of dexamethasone on fibroblastproliferation in NP compared to NM, might be initially
explained by tissue/cell desensitisation due to the previous
GC treatment of the NP patients. However, the long wash-
out period included with the generation of the cultured
fibroblast lines, which in total was at least of five weeks,
together with the fact that previous studies report that in
vivo GC therapy only provokeseif any21,22e a transient
down regulation of the GC receptor23 would not favour this
hypothesis.
In contrast to our results, two studies undertaken on NP
fibroblasts show that GCs decrease proliferation.17,18 An
increase in 3H-thymidine incorporation induced by dexa-
methasone has been reported in bronchial fibroblasts
derived from mild-to-moderate asthmatics, compared with
those obtained from non-asthmatic subjects.15,24 Surpris-
ingly, dexamethasone decreased 3H-thymidine incorpora-
tion in fibroblasts from severe asthmatics.24 More recently,
Fouty and co-workers16 reported that dexamethasone also
increased proliferation (i.e., nearly doubled the number of
cells in the S phase) of fibroblasts from patients with
moderate asthma, whereas it had no effect on normal
control fibroblasts. GCs have, however, proved to decrease
proliferation induced by a variety of stimuli of fibroblasts
from non-diseased peripheral lung tissue obtained from
patients undergoing lung resection.2527 Finally, GCs have
been found to decrease28,29 as well as increase prolifera-
tion of human foetal lung fibroblasts.30
One possible explanation to the different response to GCs
between the nose and the bronchi could be ascribed to
differences in the potency of the GC used. However, the
same GC e dexamethasone e increased proliferation of
bronchial fibroblasts from asthmatic patients,16 whereas, as
we showhere, it had no significant effect on the proliferation
224 L. Pujols et al.of fibroblasts from patients with NPs and asthma. Other
methodological aspects, such as the period of analysis, the
cell density or cell culture age at the time of analysis, the
stimulus used to induce proliferation or the technique used
to evaluate proliferation, could explain the different
response between upper and lower airway fibroblasts.
Finally, we cannot rule out the possibility that fibroblasts
from the nose are phenotypically different, and therefore
behave differently, from fibroblasts from the lower airways.
Indeed, based onmorphologic and functional characteristics
of fibroblasts isolated from proximal airways and distal lung
parenchyma, Kotaru and co-workers31 described at least two
distinct phenotypesof fibroblastin the lung.
The involvement of airway fibroblasts in fibrogenic
responses includes their capacity to produce ECM. We
sought to examine the production of collagens and its
regulation by GCs in nasal fibroblasts, which had not been
previously investigated. We found that TGF-b, but not 5%
FBS, significantly up-regulated the expression of collagens
in both NM and NP fibroblasts. The increase induced by TGF-
b is probably the result of the phenotypic transformation of
fibroblasts to myofibroblasts, which are the major
producers of ECM proteins.32 Dexamethasone did not exert
any significant effect on TGF-b-induced collagen expression
in fibroblasts from either NM or NPs, nor did it decrease
collagen expression in fibroblasts incubated with a much
less potent fibrogenic stimulus, i.e. 5% FBS. Our findings
concur with a previous study showing that in vivo treatment
of patients with NPs with topical GCs does not decrease
collagen deposition.4 Our results also concur with in vivo
studies showing no effect of GCs on collagen expression and
synthesis induced by different stimuli in both primary lung
fibroblasts25 and bronchial fibroblasts from normal and
asthmatic subjects.33 Indeed, collagen synthesis and ECM
deposition induced by incubation of fibroblasts with 5e10%
foetal calf serum are increased by GC treatment.26,28
Fibroblasts help regulate physiological functions, as well
as inflammatory and immunological responses, by
producing various growth factors and cytokines.5 Previous
studies reported GCs’ ability to inhibit the release of
various cytokines, including IL-6 and IL-8, by stimulated
lung fibroblasts.25,26,29,34 We aimed to investigate whether
there was a different sensitivity to dexamethasone inhibi-
tion of IL-6 and IL-8 in NM and NP fibroblasts. Dexametha-
sone dose-dependently decreased FBS-induced IL-6 and IL-8
production in both NM and NP fibroblasts. For both cyto-
kines, however, NP fibroblasts appeared to be less sensitive
to the inhibitory effect of a sub-maximal concentration of
dexamethasone (108M) compared to NM fibroblasts. The
inhibitory effect of GCs on cytokine production is caused by
various mechanisms, including repression of transcription
factors such as NF-kB and AP-1, destabilization of the
cytokine mRNA and transactivation of GC target genes such
as mitogen-activated protein kinase phosphatase-1 and GC-
induced leucine zipper.34,35
In summary, our study shows that fibroblasts from
patients with NPs and asthma who have a poor clinical
response to GC treatment, display a relative resistance to
the anti-proliferative effects of GCs, compared to fibroblasts
from control nasal mucosa. In addition, GCs failed to inhibit
collagen expression in any fibroblast type. In contrast, GCs
effectively down-regulated IL-6 and IL-8 production by nasalfibroblasts, though NP fibroblasts were less sensitive to
dexamethasone than NM fibroblasts. Overall, our findings
reinforce the concept that GCs are less effective in
reducing fibrosis and remodelling of the airways than in
reducing inflammation. Our results also suggest that the
impaired sensitivity of nasal polyp fibroblasts to the in
vitro anti-proliferative and anti-inflammatory effects of
glucocorticoids concurs in part with the poor clinical
response that these nasal polyp patients show to gluco-
corticoid treatment.
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